seeking to verify employment, please visit www.theworknumber.com or call +1-800-367-2884 and select "I'm a Verifier." Please be prepared to provide the following information: Employer Name or Code: Vertex Pharmaceuticals, Inc. Employer Code: 18336 ...
Vertex Pharmaceuticals, Inc. +1-617-341-6100(North American Headquarters);+44 2032 045100(International Headquarters) Media (reporters & media outlets only): mediainfo@vrtx.comor+1-617-341-6992(North America);+44 20 3204 5275(U.K., Europe & Australia)...
Key ParametersVertex Pharmaceuticals IncAbbVie IncNovartis AGArcturus Therapeutics Holdings IncKrystal Biotech Inc Headquarters United States of America United States of America Switzerland United States of America United States of America City Boston North Chicago Basel San Diego Pittsburgh State/Province Mas...
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, an...
Headquarters:Boston Industry:Pharmaceuticals CEO:Reshma Kewalramani Website:https://www.vrtx.com/ Ticker:VRTX Company type:Public Revenues ($M):$9,869 Profits ($M):$3,620 Market value ($M):$107,975 Number of employees:5,236 Market value as of March 28, 2024.Vertex Pharmaceuticals stock ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and
10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement und...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to ...
30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-cont...
8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) fo...